Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jakob Solgaard JensenPeter Ejvin WeekeLia Evi BangDan Eik HøfstenMaria Sejersten RipaAnne-Marie SchjerningJuliane Elizabeth TheiladeLars Valeur KøberGunnar Hilmar GislasonJannik PallisgaardPublished in: BMJ open (2019)
Patients treated with PCSK9i were rare, characterised by having IHD and had received various and intensive conventional LLT prior to PCSK9i initiation in agreement with current international guidelines.